background

Basic Info

SeqBiome is a world leading microbiome contract research company, providing first in class technical and scientific services to researchers in leading companies in the Pharma, Food, and Nutrition industries and to academic researchers in top Universities.

SeqBiome measures, analyzes, and interprets the microbiome using state-of-the-art tools, partnering with industry and academia to offer custom sequencing and bioinformatics services. We are committed to helping our customers derive actionable insights from their projects.

Why work with us

SeqBiome offers an end-to-end Microbiome analysis service for our customers. We add most value to our customers by being involved early in their study and we can assist them with Statistical Study Design, Sample Processing, Metagenomic Sequencing, Compositional and Functional Microbiome Analysis, Biostatistical and Bioinformatic Analysis, and Publication/Patent Ready Outputs.

In addition to our direct services, through our partner network we can offer access to in vitro Gut simulation studies, Metabolomics and state-of-the-art sampling techniques for upper Gastrointestinal microbiome studies. With over 780 peer-reviewed publications in our team, we have developed the most up-to-date datasets, pipelines and analysis tools to provide the highest quality service.

Clients (6)

UNVERIFIED

Nestlé

Nestle is a multinational food and beverage company that offers a wide range of products including coffee, bottled water, baby food, pet food, and confectionery.

UNVERIFIED

Johnson & Johnson

Johnson & Johnson is the largest and most broadly based healthcare company in the world. They engage in the research and development, manufacture, and sale of a range of products in the heal...

UNVERIFIED

Freya Biosciences

Pharma-Life Science Lab

Freya™ is a clinical-stage company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproduct...

UNVERIFIED

DSM Firmenich

Food & Beverages

Our nutrition, health, and beauty solutions build on years of work: over a century of cutting-edge science, breakthrough innovation, and passionate co-creation, to be precise. With our rich ...

Brochure

Company focus

Services

Food & Beverage
Food Ingredients
Life Sciences & Health Tech
Health Tech
Wellness & Fitness
Sports Tech & Sporting Goods
Player Performance & Wearables
Pharma
Clinical Trial Services
Healthcare
Pharma Services

Industries

Biotechnology
Dairy
Food & Beverages
Healthcare
Medical Devices
Pharmaceutical & Biopharmaceutical
Veterinary
Wellness and Fitness
Pharma-Life Science Lab
Agriculture
Animal Health
Laboratories
Research Centres
Universities

Projects or Case studies (3)

Microbiome links with diabetes and cancer immunotherapy jointly published with Roche

Microbiome links with diabetes and cancer immunotherapy jointly published with Roche

-

Our CEO Marcus Claesson was the last author on a joint publication in Immuno Horizons by scientists from SeqBiome, University College Cork and Basel-based Hoffmann-La Roche. While the contribution of the gut microbiome to the onset of Type 1 diabetes (T1D) is already known, the role of new anti-PD-1 cancer immunotherapies is less clear. The team used a non-obese diabetic mouse model to show that anti–PD-1 treatment and T1D altered both microbiota composition and diversity over time. Insulin-regulating bacteria potentially capable of reducing glucose levels were also identified, including an increase of mucin-degrading Akkermansia muciniphila. To modulate the gut microbiome might thus be a promising approach to mitigate some adverse effects associated with immunotherapies. https://seqbiome.com/microbiome-links-with-diabetes-and-cancer-immunotherapy-roche/

Seqbiome expert microbiome analysis partner on the first placebo-controlled trial of vaginal microbiota transplantation

Seqbiome expert microbiome analysis partner on the first placebo-controlled trial of vaginal microbiota transplantation

July 2024 - July 2024

SeqBiome had the pleasure of being the expert microbiome analysis partner on the first placebo-controlled trial of vaginal microbiota transplantation (VMT) in women with asymptomatic dysbiosis. Together with Atlantia Clinical Trials, we are delighted to partner with Freya Biosciences as they develop interventions for this important area of Women’s Health. https://seqbiome.com/vaginal-microbiota-transplantation-freya-trial/

SeqBiome, DSM & Atlantia Clinical Trials investigate how Fruitflow® affects TMAO and gut microbiota

SeqBiome, DSM & Atlantia Clinical Trials investigate how Fruitflow® affects TMAO and gut microbiota

- January 2023

The 4 week supplementation with the water-soluble tomato extract Fruitflow® led to decreased trimethylamine N-oxide (TMAO) levels in fasting blood and urine, along with significant changes in microbiome composition. The results (published in the Journal of Nutrition) support earlier findings that polyphenol-rich extracts can lower plasma TMAO in overweight and obese adults related to gut microbiota modulation.

Contacts

David Corr Avatar

David Corr

CEO

Social Media